MUMBAI (AFP) – Indian generic drug maker Ranbaxy Wednesday reported a bigger loss in the December quarter on falling sales and foreign exchanges losses, as it struggles with regulatory sanctions in the United States.The drugmaker posted a net loss of 10.3 billion rupees ($167.98 million) for the three months to December, higher than a loss of 1.59 billion rupees a year earlier.Overall sales were impacted by global currency depreciation in some markets, said Arun Sawhney, Ranbaxy Laboratories chief executive and managing director, in a statement.Global sales fell to 25.88 billion rupees ($422.12 million) from 28.59 billion rupees a year earlier, …read more
Source: Dunya TV
